Phase 2 diabetes dose study
A 2024 Diabetologia trial in 413 people with type 2 diabetes reported HbA1c down up to 1.68 percent and body weight down 8.7 percent across 16 weeks. Reported in the cited paper.
SourceBack to search
Weight LossMetabolic
Survodutide
Survodutide is an investigational dual glucagon and GLP-1 receptor agonist from Boehringer Ingelheim, licensed from Zealand Pharma, studied for obesity and metabolic liver disease. It holds FDA Breakthrough Therapy designation for MASH but is not approved.
- Lowest cost / mg
- $6.25/mg
- at Peptide Labs Inc
- Vendors listed
- 5
- In stock
- 5 of 7
- listings
- COA reports
- 6
Vendor listings
Compare Survodutide prices.
Show prices as
7 listings · Survodutide
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock15mgseen 4d ago
- Peptide Labs IncLowest $/mg
In stock10 mg · 10 vialsseen 3d ago
Out of stock10mgseen 4d ago
Out of stock10mgseen 5d ago
Overview
What is Survodutide?
Survodutide is an investigational dual glucagon and GLP-1 receptor agonist from Boehringer Ingelheim, licensed from Zealand Pharma, studied for obesity and metabolic liver disease. It holds FDA Breakthrough Therapy designation for MASH but is not approved.
- Weight Management
- Liver Health
- Dual Mechanism
- Metabolic Health
What the research reports
Reported benefits of Survodutide
Outcomes described across the published Survodutide literature and ongoing study. Read each as research context, not a promised result.
- 01
Dual mechanism weight effect
Combines GLP-1 appetite suppression with glucagon driven energy expenditure, which may offer an edge over GLP-1 only agents. Reported in research settings.
- 02
Weight loss in phase 2 work
Phase 2 work reported body weight reduction of 14.9 percent against 2.8 percent on placebo in adults with obesity. Noted across the published research record.
- 03
Liver disease study record
Phase 2 data reported resolution of metabolic liver disease without fibrosis progression in 62 percent against 14 percent on placebo. Reported in research settings.
- 04
Glycaemic improvement data
A phase 2 trial in type 2 diabetes reported HbA1c down up to 1.68 percent with 8.7 percent body weight reduction over 16 weeks. Reported in research settings.
- 05
Breakthrough therapy status
The FDA granted Breakthrough Therapy status for non-cirrhotic MASH with moderate or advanced fibrosis in September 2024. Reported in research settings.
Dosage and protocol
Survodutide dosage and protocol
Phase 3 obesity trials escalate to a 6.0 mg weekly target, with liver disease protocols using 4.8 mg or 6.0 mg across 48 to 72 weeks of the clinical study programme subcutaneously given.
- Route
- Subcutaneous injection
- Example range
- 2.4-6.0 mg
- Frequency
- Once weekly
- Timing
- Once weekly, consistent day, any time, with or without meals.
Clinical evidence
Clinical evidence for Survodutide
The published record for Survodutide, labeled by strength so you can see what is settled and what is emerging.
SYNCHRONIZE phase 3 design
A 2025 Obesity paper set out two phase 3 trials in 1,481 adults, reporting reduced body weight and at least 5 percent loss with and without type 2 diabetes. Reported in the cited paper.
SourcePhase 2 subgroup analysis
A 2025 analysis of 387 participants reported reduced body weight and waist circumference with comparable safety across sex and baseline BMI subgroups. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- Semaglutide
- Overlapping GLP-1 activity. No trial has tested the two agents together in the same protocol.
- Mazdutide peptide
- Both are glucagon and GLP-1 dual agonists, so combining duplicates the same two receptor targets.
- Insulin therapy
- The glucagon component raises hepatic glucose output, making glucose monitoring more important.
- Sulfonylureas
- Combined glucose lowering raises hypoglycaemia risk and needs clinical review before use. Confidence: emerging.
Questions
Frequently asked questions.
What is Survodutide?
Survodutide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Survodutide?
Survodutide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Survodutide work?
Like other research peptides, Survodutide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Survodutide for research use only?
Yes, products like Survodutide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Survodutide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
